Tag - PRNB

Developments

Principia Biopharma reports data from Phase 1 metastatic bladder cancer trial

Principia Biopharma (NASDAQ:PRNB) reported that PRN1371 was well tolerated in the dose escalation portion of its Phase 1 trial in adult patients with advanced solid tumors. PRN1371, a fibroblast growth factor receptor...

May 21, 2019

Developments

Principia Biopharma doses first patient in Phase 2b MS trial

Principia Biopharma (NASDAQ:PRNB) has dosed the first patient in its Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS). Neuroinflammation and an increase in the number of B cells in...

May 15, 2019

Tag - PRNB

Principia Biopharma reports data from Phase 1 metastatic bladder cancer trial

Principia Biopharma doses first patient in Phase 2b MS trial

General

More